Strategic partnerships have become one of the biggest growth engines in the global animal health industry. Instead of developing every product independently, companies are increasingly joining forces to discover, develop, manufacture and commercialize new veterinary medicines, vaccines, diagnostics and animal health technologies.
A newly updated industry report, “Global Animal Health Partnering Terms and Agreements 2017 to 2026,” provides one of the most comprehensive reviews of this trend. Published by ResearchAndMarkets.com, the report examines more than 280 animal health partnering agreements announced since 2017, offering valuable insights into how collaboration has become central to innovation and commercial growth across the veterinary sector.
Collaboration Is Becoming the New Business Model
Developing a new veterinary medicine or diagnostic can take years of research, significant investment and regulatory approvals. As scientific complexity increases, companies are choosing partnerships to share expertise, reduce development risk and accelerate product launches.
According to the report, many partnerships now evolve through multiple stages. A collaboration may begin with joint research and later expand into licensing, manufacturing, distribution or global commercialization agreements. This flexible approach allows companies to combine scientific strengths while reaching new markets more quickly.
More Than 280 Deals Reveal Changing Industry Priorities
The report analyzes over 280 partnering agreements covering virtually every segment of the animal health industry. These include collaborations involving:
-
Veterinary pharmaceuticals
-
Animal vaccines
-
Veterinary diagnostics
-
Companion animal healthcare
-
Livestock health technologies
-
Digital animal health platforms
-
Precision livestock solutions
-
Animal nutrition innovations
Rather than focusing only on the largest transactions, the study examines partnerships across different company sizes, development stages and technology platforms, providing a broader picture of how innovation is being commercialized globally.
Identifying the Most Active Dealmakers
Another key feature is its analysis of the industry’s most active partnering companies. The report profiles leading organizations involved in animal health collaborations and categorizes deals by:
-
Technology type
-
Therapy area
-
Stage of development
-
Deal structure
-
Company
-
Financial value
This makes it easier for investors, licensing teams and corporate strategists to identify companies that are actively expanding through partnerships rather than acquisitions alone.
Partnerships Are Expanding Beyond Traditional Pharmaceuticals
The animal health industry is no longer limited to vaccines and medicines. Many of today’s partnerships focus on rapidly growing areas such as:
-
Artificial intelligence in veterinary diagnostics
-
Molecular diagnostics
-
Biologics and monoclonal antibodies
-
Microbiome-based therapies
-
Livestock monitoring technologies
-
Precision nutrition
-
Digital herd management
-
Companion animal wellness solutions
These newer technologies often require expertise from multiple scientific disciplines, making partnerships more attractive than traditional in-house development.
Why This Matters for the Animal Health Industry
The report highlights a broader shift taking place across the global veterinary sector. Instead of competing alone, companies are increasingly building ecosystems of partners that contribute different capabilities—from scientific discovery and manufacturing to regulatory expertise and global distribution.
This collaborative approach offers several advantages:
-
Faster product development
-
Lower research costs
-
Shared commercial risk
-
Access to new technologies
-
Expansion into international markets
-
Stronger innovation pipelines
